Q3 2024 Earnings Forecast for Eli Lilly and Company Issued By Leerink Partnrs (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Analysts at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for Eli Lilly and Company in a report issued on Wednesday, May 1st. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $3.75 per share for the quarter, up from their previous forecast of $3.35. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $13.83 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company’s Q4 2024 earnings at $4.82 EPS, FY2024 earnings at $13.56 EPS, FY2025 earnings at $20.03 EPS, FY2026 earnings at $25.61 EPS, FY2027 earnings at $32.51 EPS and FY2028 earnings at $39.87 EPS.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the prior year, the company posted $1.62 EPS. The business’s revenue was up 26.0% compared to the same quarter last year.

Other equities analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research report on Wednesday, February 21st. Finally, Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $734.97 on Friday. The company has a market cap of $698.52 billion, a PE ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The firm has a 50-day simple moving average of $761.06 and a 200 day simple moving average of $671.38. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $5,992,890,000. International Assets Investment Management LLC boosted its holdings in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $682,139,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $435,736,000. Finally, Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.